Aldeyra Therapeutics, Inc

(NASDAQ:ALDX)

Latest On Aldeyra Therapeutics, Inc (ALDX):

Date/Time Type Description Signal Details
2023-05-06 12:15 ESTNewsBuy Aldeyra Therapeutics For Consecutive RunupsN/A
2023-05-04 22:01 ESTNewsAldeyra Therapeutics GAAP EPS of -$0.27 beats by $0.02N/A
2023-04-12 00:18 ESTNewsAldeyra Therapeutics gains amid takeover speculationN/A
2023-03-09 12:50 ESTNewsAldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10N/A
2023-03-09 12:49 ESTNewsAldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-02 12:50 ESTNewsFDA accepts for priority review Aldeyra's ADX-2191 application in retinal cancerN/A
2023-03-01 07:09 ESTNewsAldeyra Therapeutics: Catalyst Rich 2023 Holds Promise But Also RiskN/A
2023-02-28 16:08 ESTNewsAldeyra gains on safety data for dry eye disease candidateN/A
2023-02-07 16:03 ESTNewsAldeyra stock rises as dry eye disease drug gets FDA reviewN/A
2022-12-21 17:39 ESTNewsAldeyra files for FDA approval of ADX‑2191 for rare eye cancerN/A
2022-12-11 14:35 ESTNewsAldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar MarketN/A
2022-11-29 20:27 ESTNewsAldeyra Therapeutics seeks FDA approval of its treatment for dry eye disease symptomsN/A
2022-11-11 05:51 ESTNewsAldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-10 12:39 ESTNewsAldeyra Therapeutics GAAP EPS of -$0.25 beats by $0.10N/A
2022-11-09 19:54 ESTNewsAldeyra Therapeutics Q3 2022 Earnings PreviewN/A
2022-10-06 08:03 ESTNewsAldeyra stock rises as eye disorder drug ADX-2191 meets main goal in part 1 of phase 3 trialN/A
2022-09-19 18:38 ESTNewsAldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOAN/A
2022-09-16 05:21 ESTNewsAldeyra Therapeutics (ALDX) presents at H.C. Wainwright 24th Annual Global Investment Conference - SlideshowN/A
2022-09-14 18:07 ESTNewsAldeyra Therapeutics on track to submit new drug application for dry eye disease treatmentN/A
2022-08-05 14:22 ESTNewsAldeyra Therapeutics GAAP EPS of -$0.30 beats by $0.02N/A
2022-08-05 14:21 ESTNewsAldeyra Therapeutics stock rises 13% on Q2 beat with eyes on approval path for reproxalapN/A
2022-08-05 14:21 ESTNewsAldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-04 07:32 ESTNewsAldeyra Therapeutics: Poised For Dry Eye Disease Therapy MonetizationN/A
2022-07-12 22:36 ESTNewsAldeyra says trial for dry eye disease candidate reached key goalsN/A
2022-06-08 15:04 ESTNewsAldeyra stock soars as dry eye disease drug meets main goal in late stage studyN/A
2022-05-18 21:23 ESTNewsAldeyra says post-hoc analysis shows its eye therapy reduced ocular rednessN/A
2022-05-05 20:57 ESTNewsAldeyra Therapeutics GAAP EPS of -$0.29 beats by $0.04N/A
2022-05-05 20:56 ESTNewsAldeyra Therapeutics Inc. (ALDX) CEO Dr. Todd Brady on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-04 22:11 ESTNewsAldeyra Therapeutics Q1 2022 Earnings PreviewN/A
2022-04-29 02:34 ESTNewsAldeyra Therapeutics CFO steps down, interim CFO appointedN/A
2022-04-06 11:50 ESTNewsAldeyra Therapeutics, Inc. 2021 Q4 - Results - Earnings Call PresentationN/A
2022-03-29 21:35 ESTNewsMid-stage trials show proof of concept for Aldeyra immune-mediated disease candidateN/A
2022-03-18 11:16 ESTNewsAldeyra Therapeutics GAAP EPS of -$1.07 beats by $0.02N/A
2022-03-18 11:15 ESTNewsAldeyra Therapeutics' (ALDX) CEO Todd Brady on Q4 2021 Results - Earnings Call TranscriptN/A
2022-03-09 02:51 ESTNewsAldeyra Therapeutics starts phase 2 trial of ADX-2191 to treat rare eye disordersN/A
2022-02-18 08:40 ESTNewsAldeyra Therapeutics Stock: An Undervalued Biotech With Upcoming CatalystsN/A
2022-01-12 00:38 ESTNewsAldeyra reports positive top-line data from Phase 2 reproxalap study in dry eye diseaseN/A
2022-01-05 00:54 ESTNewsAldeyra Therapeutics completes enrollment in part 1 of phase 3 study of eye disorder drugN/A
2021-12-24 04:10 ESTNewsAldeyra Therapeutics: Tranquility's Setback Creates A Buying Opportunity If You Believe In ReproxalapN/A
2021-12-21 16:09 ESTNewsAldeyra defended at Citi despite setback to dry eye disease study for reproxalapN/A
2021-12-20 21:54 ESTNewsAldeyra crashes on setback to dry eye disease study for reproxalapN/A
2021-12-01 17:11 ESTNewsAldeyra Therapeutics (ALDX) Investor Presentation -SlideshowN/A
2021-11-02 11:38 ESTNewsAldeyra Therapeutics posts results from mid-stage reproxalap dry eye disease trialN/A
2021-10-28 16:20 ESTNewsAldeyra Therapeutics EPS misses by $0.01N/A
2021-10-28 16:19 ESTNewsAldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2021 Results - Earnings Call TranscriptN/A
2021-09-30 08:46 ESTNewsRevisiting Aldeyra TherapeuticsN/A
2021-09-21 11:29 ESTNewsAldeyra Therapeutics (ALDX) Investor Presentation - SlideshowN/A
2021-08-05 21:31 ESTNewsAldeyra Therapeutics EPS misses by $0.03N/A
2021-08-05 21:28 ESTNewsAldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-04 23:14 ESTNewsAldeyra Therapeutics shares rise after FDA orphan drug status for ADX-2191N/A

About Aldeyra Therapeutics, Inc (ALDX):

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of primary vitreoretinal lymphoma. The company's portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative diseases and covid-19; and reactive aldehyde species that are pro-inflammatory (RASP) scavengers, such as ADX-629 for treating autoimmune diseases, allergy, and covid-19, as well as ADX-103 for the treatment of retinal diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is headquartered in Lexington, Massachusetts.

ALDX Quotes by TradingView

See Advanced Chart

General

  • Name Aldeyra Therapeutics, Inc
  • Symbol ALDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 11
  • Fiscal Year EndDecember
  • IPO Date2014-05-02
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.aldeyra.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 9.79
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.15
  • Next Year EPS Estimate -$1.15
  • Next Quarter EPS Estimate -$0.29
  • Return on Assets -27%
  • Return on Equity -70%
  • Earnings Per Share -$2.00
  • Revenue Per Share $0
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 548.54 million
  • EBITDA -46566628
  • Analyst Target Price $25
  • Book Value Per Share $1.54
View More

Share Statistics

  • Shares Outstanding 47.25 million
  • Shares Float 37.94 million
  • % Held by Insiders 228%
  • % Held by Institutions 67.35%
  • Shares Short 1.8 million
  • Shares Short Prior Month 1.73 million
  • Short Ratio 1.68
  • Short % of Float 4%
  • Short % of Shares Outstanding 4%
View More

Technicals

  • Beta 1.62
  • 52 Week High $14.62
  • 52 Week Low $1.81
  • 50 Day Moving Average 11.98
  • 200 Day Moving Average 8.67
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Aldeyra Therapeutics, Inc (ALDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Aldeyra Therapeutics, Inc (ALDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-11$N/A-$0.30-$0.300.43%
2020-09-302020-11-05$N/A-$0.23-$0.2715.53%
2020-06-302020-08-06$N/A-$0.25-$0.3527.91%
2020-03-312020-05-07$N/A-$0.34-$0.4626.8%
2019-12-312020-03-12$N/A-$0.48-$0.7031.1%
2019-09-302019-11-07$N/A-$0.69-$0.56-23.68%
2019-06-302019-08-08$N/A-$0.49-$0.49-0.64%
2019-03-312019-05-09$N/A-$0.58-$0.44-32.33%
2018-12-312019-03-08$N/A-$0.39-$0.439.07%
2018-09-302018-11-14$N/A-$0.52-$0.48-9.47%
2018-06-302018-08-09$N/A-$0.46-$0.43-8.24%
2018-03-312018-05-15$N/A-$0.43-$0.38-14.15%
2017-12-312018-03-29$N/A-$0.36-$0.32-13.39%
2017-09-302017-11-09$N/A-$0.32-$0.359.22%
2017-06-302017-08-07$N/A-$0.35-$0.375.41%
2017-03-312017-05-15$N/A-$0.37-$0.35-7.25%
2016-12-312017-03-30$N/A-$0.35-$0.4623.08%
2016-09-302016-11-14$N/A-$0.38-$0.417.32%
2016-06-302016-08-10$N/A-$0.41-$0.447.24%
2016-03-312016-05-09$N/A-$0.51-$0.50-2.51%
2015-12-312016-03-30$N/A-$0.46-$0.37-24.32%
2015-09-302015-11-12$N/A-$0.35-$0.30-16.67%
2015-06-302015-08-11$N/A-$0.27-$0.3522.86%
2015-03-312015-05-13$N/A-$0.32-$0.3815.79%
2014-12-312015-03-19$N/A-$0.30-$0.4025%
2014-09-302014-11-10$N/A-$0.36-$0.32-12.5%
2014-06-302014-08-04$N/A-$1.56-$0.53-194.34%
2014-03-312014-05-28$N/A-$0.18

Aldeyra Therapeutics, Inc (ALDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Aldeyra Therapeutics, Inc (ALDX) Chart:

Aldeyra Therapeutics, Inc (ALDX) News:

Below you will find a list of latest news for Aldeyra Therapeutics, Inc (ALDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Aldeyra Therapeutics, Inc (ALDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.51.5CALL0 49756.34TRUE00
2024-05-1750.1CALL10 558100.81FALSE00
2024-05-177.50.05CALL0 200FALSE00
2024-05-172.50.05PUT0 70FALSE00
2024-05-1751.05PUT0 3092.13TRUE00
2024-05-177.50PUT0 0269.96TRUE00
2024-06-212.51.35CALL1 137284.9TRUE1.350
2024-06-2150.23CALL1 90987.51FALSE-0.02-0.08
2024-06-217.50.06CALL0 2680FALSE00
2024-06-212.50.08PUT0 1790FALSE00
2024-06-2151.35PUT0 160104.3TRUE00
2024-06-217.54.28PUT0 9191.25TRUE00
2024-09-202.51.54CALL0 61215.89TRUE00
2024-09-2050.55CALL0 143286.17FALSE00
2024-09-207.50.2CALL0 31095.06FALSE00
2024-09-202.50.2PUT0 8185.52FALSE00
2024-09-2051.35PUT0 1286.68TRUE00
2024-09-207.53.19PUT0 494.22TRUE00
2024-12-202.50CALL0 0242.62TRUE00
2024-12-2050.9CALL21 094.08FALSE0.90
2024-12-207.50.45CALL30 2092.44FALSE-0.09-0.17
2024-12-202.50.3PUT0 293FALSE00
2024-12-2050PUT0 094.77TRUE00
2024-12-207.50PUT0 093.75TRUE00
2025-01-172.52.02CALL0 14574.45TRUE00
2025-01-1751.02CALL0 180594.26FALSE00
2025-01-177.50.55CALL0 208295.19FALSE00
2025-01-17100.35CALL0 36797.19FALSE00
2025-01-1712.50.35CALL0 6897.26FALSE00
2025-01-172.50.35PUT0 76195.52FALSE00
2025-01-1752PUT0 20181.07TRUE00
2025-01-177.53.7PUT0 3089.93TRUE00
2025-01-17106.87PUT0 0107.65TRUE00
2025-01-1712.50PUT0 0142.23TRUE00
2026-01-162.52.52CALL0 5299.39TRUE00
2026-01-1651.8CALL0 864201.04FALSE00
2026-01-167.51CALL0 590FALSE00
2026-01-16100.4CALL0 20FALSE00
2026-01-1612.51.42CALL0 512100.35FALSE00
2026-01-162.50.8PUT0 2393.67FALSE00
2026-01-1652.25PUT0 53100.01TRUE00
2026-01-167.50PUT0 0115.95TRUE00
2026-01-16106.8PUT0 3100.11TRUE00
2026-01-1612.50PUT0 0115.92TRUE00

Latest ALDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST100$3.345
Jun 13, 2022 7:59 PM EST170$3.345
Jun 13, 2022 7:59 PM EST10$3.345
Jun 13, 2022 7:59 PM EST100$3.345
Jun 13, 2022 7:59 PM EST30$3.345

Aldeyra Therapeutics, Inc (ALDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520167714/0001193125-20-167714-index.htm
2018-07-26UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1341235/000000000018022951/0000000000-18-022951-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000031506619000826/0000315066-19-000826-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000031506620000826/0000315066-20-000826-index.htm
2020-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000083423720008145/0000834237-20-008145-index.htm
2020-07-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000083423720010003/0000834237-20-010003-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318015766/0000899243-18-015766-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318015767/0000899243-18-015767-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318015769/0000899243-18-015769-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318015770/0000899243-18-015770-index.htm
2018-06-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318015771/0000899243-18-015771-index.htm
2018-08-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318020972/0000899243-18-020972-index.htm
2018-08-013Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318020978/0000899243-18-020978-index.htm
2018-08-014Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924318020988/0000899243-18-020988-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/0000899243-19-006729-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319006730/0000899243-19-006730-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319006732/0000899243-19-006732-index.htm
2019-03-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319006734/0000899243-19-006734-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319015819/0000899243-19-015819-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319015820/0000899243-19-015820-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319015821/0000899243-19-015821-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319015822/0000899243-19-015822-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319015824/0000899243-19-015824-index.htm
2019-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023128/0000899243-19-023128-index.htm
2019-09-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023129/0000899243-19-023129-index.htm
2019-09-104Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023265/0000899243-19-023265-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm
2019-09-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm
2019-09-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm
2019-09-164Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023628/0000899243-19-023628-index.htm
2019-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm
2019-09-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023719/0000899243-19-023719-index.htm
2019-09-174/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023735/0000899243-19-023735-index.htm
2019-09-194Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023923/0000899243-19-023923-index.htm
2019-09-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319023982/0000899243-19-023982-index.htm
2019-09-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319024225/0000899243-19-024225-index.htm
2019-10-024Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319024582/0000899243-19-024582-index.htm
2019-12-184Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924319029509/0000899243-19-029509-index.htm
2020-01-153Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320001258/0000899243-20-001258-index.htm
2020-01-154Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320001261/0000899243-20-001261-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/0000899243-20-007060-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320007064/0000899243-20-007064-index.htm
2020-03-044Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320007067/0000899243-20-007067-index.htm
2020-03-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320007447/0000899243-20-007447-index.htm
2020-03-064/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320007448/0000899243-20-007448-index.htm
2020-03-174Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320008616/0000899243-20-008616-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016177/0000899243-20-016177-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016180/0000899243-20-016180-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016181/0000899243-20-016181-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016182/0000899243-20-016182-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016183/0000899243-20-016183-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320016185/0000899243-20-016185-index.htm
2020-07-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000089924320019004/0000899243-20-019004-index.htm
2019-09-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000090266419003845/0000902664-19-003845-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000090266420000962/0000902664-20-000962-index.htm
2018-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000090445418000424/0000904454-18-000424-index.htm
2019-01-22SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000090445419000069/0000904454-19-000069-index.htm
2019-03-284Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm
2019-06-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000090445419000466/0000904454-19-000466-index.htm
2020-01-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000090445420000020/0000904454-20-000020-index.htm
2020-06-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000090445420000398/0000904454-20-000398-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000101359419000164/0001013594-19-000164-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000101359420000132/0001013594-20-000132-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000117891319000432/0001178913-19-000432-index.htm
2018-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518188147/0001193125-18-188147-index.htm
2018-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518203119/0001193125-18-203119-index.htm
2018-07-20S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1341235/000119312518222562/0001193125-18-222562-index.htm
2018-07-25CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1341235/000119312518225751/0001193125-18-225751-index.htm
2018-07-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518232408/0001193125-18-232408-index.htm
2018-08-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518243481/0001193125-18-243481-index.htm
2018-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000119312518244346/0001193125-18-244346-index.htm
2018-09-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518281789/0001193125-18-281789-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518283160/0001193125-18-283160-index.htm
2018-09-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1341235/000119312518283947/0001193125-18-283947-index.htm
2018-09-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1341235/000119312518287518/0001193125-18-287518-index.htm
2018-09-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518287591/0001193125-18-287591-index.htm
2018-11-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518326140/0001193125-18-326140-index.htm
2018-11-1410-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000119312518326837/0001193125-18-326837-index.htm
2018-11-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518331873/0001193125-18-331873-index.htm
2018-12-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312518360931/0001193125-18-360931-index.htm
2018-12-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1341235/000119312518360963/0001193125-18-360963-index.htm
2019-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519019770/0001193125-19-019770-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000119312519040933/0001193125-19-040933-index.htm
2019-02-288-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519055552/0001193125-19-055552-index.htm
2019-03-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519067948/0001193125-19-067948-index.htm
2019-03-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1341235/000119312519069189/0001193125-19-069189-index.htm
2019-03-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519085920/0001193125-19-085920-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519142173/0001193125-19-142173-index.htm
2019-06-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519166628/0001193125-19-166628-index.htm
2019-06-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519180730/0001193125-19-180730-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519216016/0001193125-19-216016-index.htm
2019-09-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519235793/0001193125-19-235793-index.htm
2019-09-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519252836/0001193125-19-252836-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519279627/0001193125-19-279627-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519286617/0001193125-19-286617-index.htm
2019-12-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312519304808/0001193125-19-304808-index.htm
2020-01-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520006782/0001193125-20-006782-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000119312520038085/0001193125-20-038085-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520045535/0001193125-20-045535-index.htm
2020-02-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000119312520047397/0001193125-20-047397-index.htm
2020-03-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520070920/0001193125-20-070920-index.htm
2020-03-12S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1341235/000119312520071672/0001193125-20-071672-index.htm
2020-04-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520105860/0001193125-20-105860-index.htm
2020-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520131009/0001193125-20-131009-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520135600/0001193125-20-135600-index.htm
2020-05-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520146738/0001193125-20-146738-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520160151/0001193125-20-160151-index.htm
2020-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520167714/0001193125-20-167714-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520188425/0001193125-20-188425-index.htm
2020-07-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1341235/000119312520191905/0001193125-20-191905-index.htm
2020-07-148-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520192321/0001193125-20-192321-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520211319/0001193125-20-211319-index.htm
2020-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1341235/000119312520286220/0001193125-20-286220-index.htm
2019-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1341235/000156459019006997/0001564590-19-006997-index.htm
2019-04-22DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1341235/000156459019012248/0001564590-19-012248-index.htm
2019-04-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1341235/000156459019012254/0001564590-19-012254-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459019018542/0001564590-19-018542-index.htm
2019-08-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459019031031/0001564590-19-031031-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459019041846/0001564590-19-041846-index.htm
2020-03-1210-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1341235/000156459020010493/0001564590-20-010493-index.htm
2020-04-27DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1341235/000156459020018862/0001564590-20-018862-index.htm
2020-04-27DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1341235/000156459020018879/0001564590-20-018879-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459020022912/0001564590-20-022912-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459020037714/0001564590-20-037714-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1341235/000156459020051290/0001564590-20-051290-index.htm
2019-02-11DNotice of Exempt Offering of Securitieshttps://www.sec.gov/Archives/edgar/data/1341235/000158274619000001/0001582746-19-000001-index.htm
2018-07-27EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1341235/999999999518001924/9999999995-18-001924-index.htm
2018-10-04CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1341235/999999999718008382/9999999997-18-008382-index.htm

Aldeyra Therapeutics, Inc (ALDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Aldeyra Therapeutics, Inc (ALDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 228%
Institutional Ownership: 6735%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-03-05David J ClarkChief Medical OfficerBuy3,503.0011,512.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319006730/0000899243-19-006730-index.htm
2020-03-16RICHARD DOUGLASDirectorBuy40,000.002.75110,000.00125,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924320008616/0000899243-20-008616-index.htm
2019-09-06David J ClarkChief Medical OfficerBuy5,000.005.0625,311.0017,878.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023265/0000899243-19-023265-index.htm
2019-09-17Ben BronsteinDirectorBuy1,700.005.859,945.0018,644.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023923/0000899243-19-023923-index.htm
2019-03-26JESSE I TREUDirectorSell96,298.0010.01963,942.981,877,091.00https://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm
2019-09-12MARTIN JOSEPH JOYCEDirectorBuy1,700.005.869,964.2119,644.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023628/0000899243-19-023628-index.htm
2020-03-02David McMullinChief Commercial OfficerBuy250,000.00257,703.00https://www.sec.gov/Archives/edgar/data/1341235/000089924320007064/0000899243-20-007064-index.htm
2020-03-02Joshua ReedChief Financial OfficerBuy250,000.00285,774.00https://www.sec.gov/Archives/edgar/data/1341235/000089924320007067/0000899243-20-007067-index.htm
2019-03-05Joshua ReedChief Financial OfficerBuy29,637.0029,637.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319006732/0000899243-19-006732-index.htm
2019-09-05Joshua ReedChief Financial OfficerBuy3,200.004.7115,072.0035,774.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023129/0000899243-19-023129-index.htm
2019-09-09RICHARD DOUGLASDirectorBuy10,000.004.9149,106.0050,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm
2019-03-05Todd C BradyPresident and CEOBuy250,000.00556,054.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319006729/0000899243-19-006729-index.htm
2019-09-09Todd C BradyPresident and CEOBuy10,000.004.8948,887.00568,991.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm
2019-09-10Todd C BradyPresident and CEOBuy10,000.005.3953,937.00578,991.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023317/0000899243-19-023317-index.htm
2019-09-13Todd C BradyPresident and CEOBuy10,000.005.7957,900.00588,991.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm
2019-09-16Todd C BradyPresident and CEOBuy3,000.006.0318,090.00591,991.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023718/0000899243-19-023718-index.htm
2019-09-10RICHARD DOUGLASDirectorBuy10,000.005.0950,857.0060,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023315/0000899243-19-023315-index.htm
2019-09-05David McMullinChief Commerical OfficerBuy4,329.004.6820,259.726,148.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023128/0000899243-19-023128-index.htm
2019-09-18Todd C BradyPresident and CEOBuy14,288.005.9184,464.94614,826.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023982/0000899243-19-023982-index.htm
2019-09-23Todd C BradyPresident and CEOBuy8,680.005.8150,432.54623,506.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319024225/0000899243-19-024225-index.htm
2020-07-09PERCEPTIVE ADVISORS LLC10% Share HolderBuy3,200,000.004.2513,600,000.006,285,458.00https://www.sec.gov/Archives/edgar/data/1341235/000089924320019004/0000899243-20-019004-index.htm
2019-09-30Todd C BradyPresident and CEOBuy8,710.005.6849,483.25632,216.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319024582/0000899243-19-024582-index.htm
2019-12-16Todd C BradyPresident and CEOBuy20,000.005.10101,908.00652,216.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319029509/0000899243-19-029509-index.htm
2019-09-11RICHARD DOUGLASDirectorBuy10,000.005.7557,529.0070,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm
2019-09-12RICHARD DOUGLASDirectorBuy10,000.006.0360,276.0080,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023539/0000899243-19-023539-index.htm
2019-09-13RICHARD DOUGLASDirectorBuy5,000.006.0030,000.0085,000.00https://www.sec.gov/Archives/edgar/data/1341235/000089924319023719/0000899243-19-023719-index.htm
2019-03-26JESSE I TREUDirectorSell445.0010.014,454.458,763.00https://www.sec.gov/Archives/edgar/data/1341235/000090445419000337/0000904454-19-000337-index.htm
2020-03-02Todd C BradyPresident and CEOBuy250,000.00902,216.00https://www.sec.gov/Archives/edgar/data/1341235/000089924320007060/0000899243-20-007060-index.htm